These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15958845)

  • 21. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.
    Schouten JN; Van der Ende ME; Koëter T; Rossing HH; Komuta M; Verheij J; van der Valk M; Hansen BE; Janssen HL
    Aliment Pharmacol Ther; 2012 Nov; 36(9):875-85. PubMed ID: 22971050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does tenofovir increase efavirenz hepatotoxicity?
    Lattuada E; Lanzafame M; Carolo G; Gottardi M; Concia E; Vento S
    AIDS; 2008 May; 22(8):995. PubMed ID: 18453862
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.
    Cotte L; Bénet T; Billioud C; Miailhes P; Scoazec JY; Ferry T; Brochier C; Boibieux A; Vanhems P; Chevallier M; Zoulim F
    J Hepatol; 2011 Mar; 54(3):489-96. PubMed ID: 21056493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early virological failure with a combination of tenofovir, didanosine and efavirenz.
    Podzamczer D; Ferrer E; Gatell JM; Niubo J; Dalmau D; Leon A; Knobel H; Polo C; Iniguez D; Ruiz I
    Antivir Ther; 2005; 10(1):171-7. PubMed ID: 15751775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EU issues warning about HAART regimen.
    AIDS Patient Care STDS; 2004 Jan; 18(1):56-7. PubMed ID: 15080094
    [No Abstract]   [Full Text] [Related]  

  • 26. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate.
    Guo Y; Fung HB
    Pharmacotherapy; 2004 Aug; 24(8):1089-94. PubMed ID: 15338857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.
    León A; Mallolas J; Martinez E; De Lazzari E; Pumarola T; Larrousse M; Milincovic A; Lonca M; Blanco JL; Laguno M; Biglia A; Gatell JM
    AIDS; 2005 Oct; 19(15):1695-7. PubMed ID: 16184042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
    Hussain S; Khayat A; Tolaymat A; Rathore MH
    Pediatr Nephrol; 2006 Jul; 21(7):1034-6. PubMed ID: 16773419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
    Irizarry-Alvarado JM; Dwyer JP; Brumble LM; Alvarez S; Mendez JC
    AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.
    Costa P; Bozzano F; Fenoglio D; Beltrame A; Cenderello G; Di Biagio A; Ferrea G; Pagano G; De Maria A
    Clin Exp Immunol; 2009 Oct; 158(1):55-63. PubMed ID: 19737231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
    Landman R; Koulla-Shiro S; Sow PS; Ngolle M; Diallo MB; Guèye NF; Le Moing V; Eymard-Duvernay S; Benalycherif A; Charpentier C; Peytavin G; Delaporte E; Girard PM;
    Antivir Ther; 2014; 19(1):51-9. PubMed ID: 23970206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.
    Karrer U; Ledergerber B; Furrer H; Elzi L; Battegay M; Cavassini M; Gayet-Ageron A; Hirschel B; Schmid P; Russotti M; Weber R; Speck RF;
    AIDS; 2005 Nov; 19(17):1987-94. PubMed ID: 16260905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience.
    Rosso R; Parodi A; Torrisi C; De Terlizzi F; Viscoli C; Vignolo M
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1265-6. PubMed ID: 20874420
    [No Abstract]   [Full Text] [Related]  

  • 34. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.
    Gianotti N; Seminari E; Fusetti G; Salpietro S; Boeri E; Galli A; Lazzarin A; Clementi M; Castagna A
    AIDS; 2004 Nov; 18(16):2205-8. PubMed ID: 15577657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
    Negredo E; Bonjoch A; Paredes R; Puig J; Clotet B
    Clin Infect Dis; 2005 Sep; 41(6):901-5. PubMed ID: 16107993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
    Kirian MA; Higginson RT; Fulco PP
    Ann Pharmacother; 2004 Oct; 38(10):1660-3. PubMed ID: 15340130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.
    Murphy MD; O'Hearn M; Chou S
    Clin Infect Dis; 2003 Apr; 36(8):1082-5. PubMed ID: 12684925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
    Tung MY; Mandalia S; Bower M; Gazzard B; Nelson M
    HIV Med; 2005 May; 6(3):151-4. PubMed ID: 15876280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
    Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.